Printer Friendly

SCHERING-PLOUGH LICENSES ORAL ANDROGEN TO SPI PHARMACEUTICALS

/NOTE TO EDITORS: The following moved earlier today as NY051. It is being retransmitted with additional information in the last paragraph./
 COSTA MESA, Calif., Jan. 10 /PRNewswire/ -- SPI Pharmaceuticals, Inc. (AMEX: SPI) and Schering-Plough Corporation (NYSE: SGP) have announced an agreement in which SPI will be the exclusive licensee in the U.S. and Puerto Rico of the Oreton Methyl line (brand of methyltestosterone tablets, USP), a prescription oral androgen to be manufactured by Schering-Plough.
 The product will be marketed by SPI Pharmaceuticals under the ICN Pharmaceuticals label as Oreton Methyl 10 (10mg), under the agreement which became effective Jan. 1, 1994. The product is professionally marketed to physicians.
 Oral androgens are intended for use by males as a replacement therapy in conditions associated with a deficiency or absence of testosterone (hypogonadism). They also are a second line therapy for advanced, inoperable metastatic (skeletal) breast cancer for women who are one to five years post-menopausal.
 SPI Pharmaceuticals, headquartered in Costa Mesa, manufactures, markets and distributes more than 600 prescription and nonprescription pharmaceuticals in over 60 countries, including North and Latin America, Western and Eastern Europe and the Far East. Schering-Plough Corporation, based in Madison, N.J., is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
 The product will be sold in bottles of 100 tablets. Oreton Methyl tablets are classified as controlled substances under the Anabolic Steroids Control Act of 1990 and have been assigned to Schedule III. Terms of the transaction were not disclosed.
 -0- 1/10/94 R
 /CONTACT: Paul Knopick of SPI, 714-545-0100, Ext. 2465/
 (SPI SGP)


CO: SPI Pharmaceuticals, Inc.; Schering-Plough Corporation ST: California, New Jersey IN: MTC SU: LIC

CK -- NY051A -- 0610 01/10/94 13:04 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 10, 1994
Words:293
Previous Article:TROPICANA(R) ACQUIRES HITCHCOCK
Next Article:TSYS REPORTS 15.1% INCREASE IN NET INCOME FOR 1993
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters